Correction: Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine

Yao-Yu Hsieh; Tsui-Chin Huang; Hsiang-Ling Lo; Jyun-Yan Jhan; Shui-Tein Chen; Pei-Ming Yang

doi:10.18632/oncotarget.26019

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine

PDF | How to cite

Oncotarget. 2018; 9:32402-32402. https://doi.org/10.18632/oncotarget.26019

Metrics: PDF 1407 views | ?

Yao-Yu Hsieh^1,2,5, Tsui-Chin Huang^1,3, Hsiang-Ling Lo^1,3, Jyun-Yan Jhan^1,3, Shui-Tein Chen^1,4 and Pei-Ming Yang^1,3

¹ PhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei, Taiwan
² Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
³ Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
⁴ Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan
⁵ Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Published: August 17, 2018

This article has been corrected: The author affiliation is given below:

Yao-Yu Hsieh^1,2,5

⁵ Department of Internal Medicine, Division of Hematology and Oncology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Original article: Oncotarget. 2016; 7:27363-27378. DOI: https://doi.org/10.18632/oncotarget.8455.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26019

Publication Alerts

Corrections:

Correction: Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine